SCHEDULE 13G/A: Deep Track Capital and Affiliates Disclose 8.10% Stake in Invivyd, Inc.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly disclosed a beneficial ownership of 8.10% in Invivyd, Inc.'s common stock.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an Amendment No. 2 to Schedule 13G, disclosing their beneficial ownership in Invivyd, Inc.
• The reporting persons collectively beneficially own 9,722,254 shares of Invivyd, Inc. common stock.
• This ownership represents 8.10% of the total outstanding common stock of Invivyd, Inc.
• The percentage is calculated based on 119,961,445 common shares outstanding as of March 11, 2025, as reported in Invivyd's 10-K filing on March 20, 2025.
• The reporting persons share both voting and dispositive power over all 9,722,254 shares.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of Invivyd, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a strong positive or negative sentiment. It is neutral in tone.

Positives

• A significant stake by an institutional investor like Deep Track Capital may signal confidence in Invivyd, Inc.'s long-term prospects.
• The passive nature of the filing (Schedule 13G) suggests the investor is not seeking to influence control, which can be viewed positively by current management.

Negatives

• The document itself does not contain negative information about Invivyd, Inc.'s performance or outlook, as it is a disclosure of ownership.

Risks

• The document does not detail specific risks related to Invivyd, Inc.'s business operations or financial health. It is a disclosure of beneficial ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Invivyd, Inc.'s future outlook.

Industry Context

This filing indicates a significant investment by a specialized biotechnology investment firm, Deep Track Capital, in Invivyd, Inc., a company operating in the biotechnology sector. Such investments are common as institutional funds seek to gain exposure to specific industries or companies they believe have growth potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and liquidity.
• Management: The passive nature of the investment (13G filing) suggests no immediate intent to influence control, which may be seen as stable for current management.

Key Dates

Keywords

Invivyd Inc., Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, Healthcare Investment